World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
29140
World Ranking
16961
National Ranking
568

Ian D. Davis publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ian D. Davis sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 514 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ian D. Davis D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ian D. Davis sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ian D. Davis is affiliated with Monash University in Australia. Their research primarily focuses on the field of Medicine, with significant specialization in Pulmonary and Respiratory Medicine, Surgery, Oncology, Radiology, Nuclear Medicine and Imaging, and Cancer Research. This multidisciplinary approach encompasses various aspects of cancer treatment and related medical fields.

The main topics covered in their research include:

  • Prostate Cancer Treatment and Research
  • Bladder and Urothelial Cancer Treatments
  • Radiopharmaceutical Chemistry and Applications
  • Cancer Immunotherapy and Biomarkers
  • Prostate Cancer Diagnosis and Treatment
  • Cancer, Lipids, and Metabolism
  • Renal Cell Carcinoma Treatment

Ian D. Davis has contributed to multiple highly cited papers in well-known medical journals. Selected recent publications are:

  • [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial (2021), The Lancet
  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial (2020), The Lancet
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 (2020), European Urology
  • Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial (2020), The Lancet Oncology
  • Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2022), The Lancet Oncology

Their frequent co-authors include:

  • Martin R. Stockler
  • Andrew Martin
  • Anthony M. Joshua
  • Michael S. Hofman
  • Shahneen Sandhu

The venues where Ian D. Davis most frequently publishes research are:

  • Journal of Clinical Oncology
  • European Urology
  • Annals of Oncology
  • British Journal of Urology
  • The Lancet Oncology

Best Publications

  • Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Tomasz M Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot

  • Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

    Cora N. Sternberg;Ian D. Davis;Jozef Mardiak;Cezary Szczylik

  • Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

    Ian D. Davis;Andrew J. Martin;Martin R. Stockler;Stephen Begbie

  • [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

    Michael S Hofman;Louise Emmett;Shahneen Sandhu;Amir Iravani

  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.

    Matthew D. Galsky;José Ángel Arranz Arija;Aristotelis Bamias;Ian D. Davis

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

    Ian D. Davis;Weisan Chen;Heather Jackson;Phillip Parente;Phillip Parente

  • A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

    Cora N. Sternberg;Robert E. Hawkins;John Wagstaff;Pamela Salman

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.

    M E Gleave;M Elhilali;Y Fradet;I Davis

  • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

    S Gillessen;A Omlin;G Attard;J S de Bono

  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

    Silke Gillessen;Gerhardt Attard;Tomasz M. Beer;Himisha Beltran

  • Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma

    Thomas E. Hutson;Ian D. Davis;Jean-Pascal H. Machiels;Paul L. De Souza

  • Tumor antigen expression in melanoma varies according to antigen and stage

    Catherine Barrow;Judy Browning;Duncan MacGregor;Ian D. Davis

  • Breast and prostate cancer: more similar than different.

    Gail Petuna Risbridger;Ian D Davis;Stephen N Birrell;Wayne D Tilley

  • Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

    Robert John Motzer;Camillo Porta;Nicholas J Vogelzang;Cora N Sternberg

  • Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.

    Andrew Kneebone;Andrew Kneebone;Carol Fraser-Browne;Gillian M Duchesne;Gillian M Duchesne;Richard Fisher

  • Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery

    Max Schnurr;Qiyuan Chen;Qiyuan Chen;Amanda Shin;Amanda Shin;Weisan Chen;Weisan Chen

  • CLINICAL ROLE OF F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR DETECTION AND MANAGEMENT OF RENAL CELL CARCINOMA

    Shakher Ramdave;Gwynne W. Thomas;Salvatore U. Berlangieri;Damien M. Bolton

  • The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells.

    Lisa M Ebert;Bee Shin Tan;Judy Browning;Suzanne Svobodova

Frequent Co-Authors

Jonathan Cebon
Jonathan Cebon La Trobe University
Andrew M. Scott
Andrew M. Scott La Trobe University
Nathan Lawrentschuk
Nathan Lawrentschuk University of Melbourne
Weisan Chen
Weisan Chen La Trobe University
Andrew J. Martin
Andrew J. Martin University of New South Wales
Eugene Maraskovsky
Eugene Maraskovsky CSL (United Kingdom)
Graham G. Giles
Graham G. Giles University of Melbourne
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
Declan G. Murphy
Declan G. Murphy King's College London
Lloyd J. Old
Lloyd J. Old Ludwig Cancer Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean pursuing a traditional MD. There are a variety of online degrees and alternative career pathways that offer rewarding opportunities in healthcare.

For those with a non-nursing bachelor’s degree, non nursing bachelor's to msn online programs allow a fast track into advanced nursing without repeating undergraduate studies. These flexible options can accelerate your transition to leadership roles within the medical field.

If you’re concerned about meeting rigorous admission standards, consider easy nursing programs to get into. Some programs focus on holistic admission criteria, making the nursing profession more accessible for a wider range of backgrounds and experiences.

For those drawn to healthcare administration, online medical billing and coding with financial aid programs offer a practical route. These programs can launch your career in medical records, billing, and insurance—roles that are in high demand.

Lastly, aspiring nurses who want to avoid standardized admissions testing might explore nursing schools that don't require teas test. This pathway can help ease the entry process, allowing you to focus on your studies and future career.

Best Scientists Citing Ian D. Davis

Trending Scientists

Recently Published Articles